OBJECTIVE: To evaluate the efficacy and tolerability of intravenous (IV) levetiracetam in refractory status epilepticus of migrating partial seizures in infancy (MPSI). METHODS: IV levetiracetam was infused in two infants, first as a loading dose of 60mg/kg in 30min, then at 30mg/kg twice a day. Both infants were continuously monitored with video-EEG before, during and after the drug trial. Blood count, liver enzymes, serum creatinine, ammonia and lactate blood levels were performed repeatedly before and after the IV levetiracetam administration. Follow-up was of 16 and 10 months. RESULTS: EEG monitoring allowed the diagnosis of MPSI, showing the typical seizures pattern in both patients. IV levetiracetam was effective in stopping status epilepticus in both infants. Levetiracetam also prevented the recurrence of status epilepticus during follow-up. No adverse reactions were observed during the infusion phase or during follow-up. CONCLUSIONS: MPSI is a newly recognized epileptic syndrome characterized by early onset of intractable partial seizures arisingly independently and sequentially from both hemispheres, migrating from one region of the brain to another and from one hemisphere to another. We report the efficacy of intravenous levetiracetam in resolving refractory status epilepticus in two infants with this new epilepsy syndrome.
OBJECTIVE: To evaluate the efficacy and tolerability of intravenous (IV) levetiracetam in refractory status epilepticus of migrating partial seizures in infancy (MPSI). METHODS: IV levetiracetam was infused in two infants, first as a loading dose of 60mg/kg in 30min, then at 30mg/kg twice a day. Both infants were continuously monitored with video-EEG before, during and after the drug trial. Blood count, liver enzymes, serum creatinine, ammonia and lactate blood levels were performed repeatedly before and after the IV levetiracetam administration. Follow-up was of 16 and 10 months. RESULTS: EEG monitoring allowed the diagnosis of MPSI, showing the typical seizures pattern in both patients. IV levetiracetam was effective in stopping status epilepticus in both infants. Levetiracetam also prevented the recurrence of status epilepticus during follow-up. No adverse reactions were observed during the infusion phase or during follow-up. CONCLUSIONS: MPSI is a newly recognized epileptic syndrome characterized by early onset of intractable partial seizures arisingly independently and sequentially from both hemispheres, migrating from one region of the brain to another and from one hemisphere to another. We report the efficacy of intravenous levetiracetam in resolving refractory status epilepticus in two infants with this new epilepsy syndrome.
Authors: Nicholas S Abend; Ana M Gutierrez-Colina; Heather M Monk; Dennis J Dlugos; Robert R Clancy Journal: J Child Neurol Date: 2011-01-13 Impact factor: 1.987
Authors: Amy McTague; Richard Appleton; Shivaram Avula; J Helen Cross; Mary D King; Thomas S Jacques; Sanjay Bhate; Anthony Cronin; Andrew Curran; Archana Desurkar; Michael A Farrell; Elaine Hughes; Rosalind Jefferson; Karine Lascelles; John Livingston; Esther Meyer; Ailsa McLellan; Annapurna Poduri; Ingrid E Scheffer; Stefan Spinty; Manju A Kurian; Rachel Kneen Journal: Brain Date: 2013-04-18 Impact factor: 13.501
Authors: Adriana Monserrath Orellana-Paucar; Tatiana Afrikanova; Joice Thomas; Yelaman K Aibuldinov; Wim Dehaen; Peter A M de Witte; Camila V Esguerra Journal: PLoS One Date: 2013-12-13 Impact factor: 3.240